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Abstract
Background The Multinational Assessment of Psoriasis
and Psoriatic Arthritis (MAPP), a population-based survey
of patients, dermatologists, and rheumatologists, was con-
ducted for better understanding of the unmet needs of
psoriasis and psoriatic arthritis (PsA) patients.
Objective To report results fromUSphysicians and patients.
Methods Adults were contacted by household telephone,
using random digit dialing, and asked to participate if they
had ever been diagnosed with psoriasis or PsA. Physicians
were identified through national databases and contacted
through random sampling methods.
Results In the USA, 1005 patients, 101 dermatologists, and
100 rheumatologists were surveyed. PsA had been diagnosed
in 270 patients (26.9 %). Of those with psoriasis alone, fewer
than 60 % (versus 85.6 % of PsA patients) had seen a
healthcare providerwithin 12 months. Joint painwas reported
by51.8 %ofpsoriasis patientswithout a diagnosis ofPsA, and
37.6 % of dermatologists cited their greatest challenge in
managing PsA patients as being differentiating PsA from
other arthritic diseases. Itching was reported by 36 % of
psoriasis patients versus 12 % of dermatologists as the most
important factor contributing to disease severity. Patients
reported lower rates of current treatment than did dermatol-
ogists and rheumatologists. Conventional oral and biologic
therapies were used by 24.9 and 17.7 % of patients, respec-
tively. Among patients who had received injectable biologics,
treatment dissatisfaction was related to long-term safety/tol-
erability, injection-related anxiety/fear, and cost.
Conclusion This large, population-based survey identified
unmet needs in themanagement of psoriasis and PsApatients
in the USA, including assessment of disease severity, PsA
diagnosis, undertreatment, and satisfaction with therapy.
Key Points
Both psoriasis and psoriatic arthritis remain
undertreated in patients with moderate to severe
disease.
Unmet needs exist in screening, assessing,
diagnosing, and treating psoriasis patients who have
symptoms of psoriatic arthritis.
Widespread dissatisfaction with current treatment
options is reflected in patients not seeing a physician
or not initiating or continuing therapies because of
concerns with long-term safety, administration
challenges, and cost.
Our findings underscore differences in perceptions
between patients and physicians regarding disease
severity and its impact on treatment selection, and
highlight the need for ongoing communication
between patients and physicians for better
understanding of perceptions of disease severity, as
well as treatment options and goals.
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1 Introduction
Psoriasis affects more than 7 million adults in the USA [1].
While the prevalence of psoriasis has remained generally
stable at approximately 3 % over the past decade [1, 2], the
incidence nearly doubled between 1970 and 2000 [3].
Patients with psoriasis report a significant impact on their
quality of life, including mental and social function [4–6].
In addition, approximately 30 % of psoriasis patients also
develop psoriatic arthritis (PsA) [7–9], which can add to
the impact on quality of life, affecting physical function
and leading to productivity loss and disability [4, 5, 10, 11].
Because of the chronic, inflammatory nature of psoriasis
and PsA, long-term systemic therapy is often necessary to
control the signs and symptoms, and to improve physical
function and quality of life for patients [7, 12]. Recent
reports have identified undertreatment and treatment dis-
satisfaction as significant barriers to optimal care of pso-
riasis and PsA patients [9, 13].
The population-based Multinational Assessment of
Psoriasis and Psoriatic Arthritis (MAPP) survey of 3426
patients and 781 dermatologists and rheumatologists in
North America and Europe was designed to evaluate the
diagnosis and ongoing management of patients with pso-
riasis and PsA from the patient and physician perspectives,
as well as evaluating unmet treatment needs. The large
volumes of data collected from the study were too exten-
sive to include in a single publication. Results from the
global patient and physician MAPP surveys, including the
US patient findings, have been published separately [14–
16]. In this report, we explore findings from all US par-
ticipants, including patients, dermatologists, and rheuma-
tologists, to further investigate similarities and differences
in attitudes toward disease severity and treatment, and to
identify opportunities to improve the care of patients with
psoriasis and PsA.
2 Methods
Abt SRBI, Inc. (New York, NY, USA) conducted the
MAPP survey between June and August 2012. The study
methodology has been reported previously [14, 16].
Briefly, this systematic household telephone survey used
random digit dialing to identify a probability sample.
Household members aged 18 years or older could partici-
pate if they had ever been diagnosed with psoriasis or PsA.
Patients did not have to be under the care of a healthcare
provider (HCP) at the time of the survey.
Dermatologists and rheumatologists were identified
through the American Medical Association/American
Osteopathic Association national database and were
contacted through random sampling methods. Dermatolo-
gists were screened to ensure that 50 % or more of their
practice was devoted to medical dermatology.
3 Results
3.1 Study Population
A total of 1005 patients with psoriasis or PsA were sur-
veyed in the USA; of these patients, 270 (26.9 %) reported
a diagnosis of PsA. The mean age of surveyed patients was
57 years, and 61.3 % were female (Table 1). Approxi-
mately 75 % of patients reported at least one comorbid
condition, with the most commonly reported conditions
being general arthritis, hypertension, depression, diabetes,
and heart disease. The mean age at symptom onset was
34 years, and the mean age at the time of patients’ psoriasis
diagnosis was 37 years. Patients with PsA reported a mean
Table 1 Patient demographics and clinical characteristics for the US
portion of the Multinational Assessment of Psoriasis and Psoriatic
Arthritis (MAPP) survey [15]
Characteristic n = 1005b
Age (years)
Mean age (median) 57 (57)
Range (minimum–maximum) 75 (18–93)
Females [n (%)] 616 (61.3)
Diagnosis of PsA [n (%)]a 270 (26.9)
Mean age at onset of psoriasis (years) 34
Mean age at diagnosis of psoriasis (years) 37






Heart disease 126 (12.5)
Cancer 76 (7.6)
Other 69 (6.9)
Ulcerative colitis 26 (2.6)
Liver disease 20 (2.0)
Crohn’s disease 14 (1.4)
Uveitis 4 (0.4)
None 247 (24.6)
The copyright for this material is owned by the National Psoriasis
Foundation, and this material is reprinted courtesy of the National
Psoriasis Foundation
PsA psoriatic arthritis
a With or without a separate diagnosis of psoriasis
b The n value reflects the total number of patients surveyed; the
actual number of patients answering each question may vary
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interval of 12.4 years between onset of skin symptoms and
onset of joint symptoms; the mean age at the time of
patients’ PsA diagnosis was 44 years.
In the US physician portion of the MAPP survey, 1716
dermatologists and 1235 rheumatologists were screened,
and 101 dermatologists and 100 rheumatologists completed
the survey (Table 2). Physicians reported an average of
18 years in practice, and 98 % reported that their practice
was office based.
More than half of the dermatologists reported that their
patients were diagnosed with psoriasis by another physi-
cian, while 41.1 % of rheumatologists reported that they
had made the diagnosis of PsA themselves. Referrals of
patients newly diagnosed with psoriasis or PsA came in
large part from primary care physicians (&55 %). The
majority of rheumatologists (73.2 %) reported being solely
responsible for prescribing decisions for PsA patients,
compared with 28.9 % of dermatologists (Table 2).
Approximately one third of the dermatologists and
rheumatologists indicated co-management of patients, most
commonly with a rheumatologist primarily being respon-
sible for prescribing decisions and a dermatologist also
monitoring skin symptoms.
3.2 Factors Affecting Disease Severity
Findings from the MAPP survey suggested that psoriasis
patients and dermatologists may assess disease severity
differently (Fig. 1a). More than one third of patients
reported that itching was the most important factor con-
tributing to their disease severity, followed by the location
and size of lesions (21.8 %). In contrast, more than three
times as many dermatologists (76.2 %) considered the
location or size of the skin lesions to be the most important
factor contributing to disease severity in their patients with
psoriasis, while only one tenth of dermatologists cited
itching (11.9 %).
Although PsA patients’ and physicians’ assessments of
factors affecting disease severity were more consistent than
those of psoriasis patients and physicians, itching contin-
ued to be rated as less important by physicians than by PsA
patients. Approximately half of the PsA patients reported
joint pain and swelling as the most important factors in
disease severity (Fig. 1b). This was followed by itching,
the location and size of the skin lesions, and flaking. The
majority of dermatologists and rheumatologists considered
joint pain or swelling to be the most important factor
contributing to severity in PsA patients; only 2 % of der-
matologists and 2 % of rheumatologists rated itching as the
most important factor contributing to disease severity.
Table 2 Physician demographics and practice characteristics for the






Number screened 1716 1235





Office based practice (%) 98.0 98.0
Hospital based practice (%) 2.0 2.0







Mean weekly number of
patients seen
161.1 114.1




Mean proportion of all visits
related to psoriasis (%)
12.9 –
Mean proportion of all visits
related to PsA (%)
3.4 15.5
Diagnosis of psoriasis (dermatologist) or skin symptoms in PsA
patients (rheumatologist) made by
Other physician 50.3 16.4
Self 33.2 41.1
Other dermatologist 6.5 39.5
Referrals of newly diagnosed psoriasis patients by
Primary care physician 56.3 –
Other dermatologist 5.3 –
Other specialist 14.4 –
Referrals of newly diagnosed PsA patients by:
Primary care physician 49.4 54.7
Other dermatologist 4.0 27.6
Other specialist 14.1 13.0
Solely responsible for
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These observations are consistent with the global
MAPP populations [14, 16] and highlight the differences
between patients and physicians in the perception of
disease severity and the factors that affect this
perception.
3.3 Assessment of Joint Pain
Of the psoriasis patients who did not have a diagnosis of
PsA, 51.8 % reported joint pain; of these, 48.1 % reported
having more than four affected joints. In contrast, der-
matologists reported a substantially lower percentage
(18.6 %) of their psoriasis patients complaining of joint
symptoms. This discrepancy may be due to variations in
assessing joint pain (which is also associated with many
inflammatory conditions beyond PsA) among patients.
However, while most dermatologists reported discussing
the possibility of developing joint disease with all
(57.4 %) or some (33.7 %) of their psoriasis patients,
87.1 % of dermatologists and 85.0 % of rheumatologists
acknowledged that PsA is likely underdiagnosed because
of failure to connect skin and joint symptoms. In addition,
37.6 % of dermatologists most often cited differentiating
PsA from other arthritic diseases as the greatest challenge
in managing PsA patients, while 25.0 % of rheumatolo-
gists cited delayed referral as one of their greatest
challenges.
3.4 Physician Attitudes: Challenges in Patient
Management
Both dermatologists and rheumatologists reported that the
management of patients with psoriasis and PsA can be
challenging. According to 68.3 % of the dermatologists,
their psoriasis patients require more time and support than
patients with other medical concerns, with 24.8 % report-
ing management of psoriasis patients as complicated and
34.7 % reporting it as time consuming. In addition, 32.7 %
of dermatologists reported that managing patients with PsA
was complicated, while 26.7 % of dermatologists said that
managing these patients was time consuming. However,
only 6.9 % of dermatologists thought they would need to
refer to or involve other specialists in the care of their PsA
patients (and only 1 % thought they would need to involve
other specialists in the care of their psoriasis patients). Of
the rheumatologists surveyed, 23 % reported that their PsA
patients require more time and support than their other
patients.
In addition to the challenges of differentiating PsA from
other arthritic conditions, dermatologists also cited chal-
lenges with the therapies for psoriasis and PsA, such as
affordability (28.7–57.4 %), lack of long-term safety
(8.9–16.8 %), and lack of effectiveness (12.9–14.9 %).
Similarly, in addition to delayed referral, rheumatologists
most often cited affordability (39 %), lack of effectiveness
Fig. 1 Top five most important
factors contributing to disease
severity in psoriasis (a) and
psoriatic arthritis (b), as
reported by patients and
physicians
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(19 %), and lack of long-term safety (9 %) of current med-
ications as the greatest challenges in treating PsA patients.
3.5 Medical Care and Treatment Patterns
3.5.1 Patient Use of Medical Care
Among the psoriasis patients, 42.6 % reported that they
had not seen an HCP in the previous 12 months. Of the
57.4 % of psoriasis patients who had seen an HCP in the
previous 12 months, 56.9 % had seen a dermatologist and
30.2 % had seen a primary care physician (Table 3). The
most common reasons that psoriasis patients cited for not
seeing an HCP were that the symptoms were not bad
enough, there were no symptoms, they did not think an
HCP could help, the current treatment was working, or
they were unable to get an appointment (Table 3).
In contrast, the majority of PsA patients (85.6 %) had
seen an HCP in the previous 12 months; these patients
reported most often seeing a rheumatologist for their PsA,
followed by a primary care physician and a dermatologist
(Table 3). The reasons cited by PsA patients for not seeing
an HCP in the previous year generally were similar to those
cited by psoriasis patients, including that their symptoms
were not bad enough, they did not think an HCP could
help, there were no symptoms, the current treatment was
working, and the cost or lack of insurance (Table 3).
3.5.2 Current Treatments
Overall, patients reported lower rates of current treatment
than dermatologists and rheumatologists, with substantial
differences noted in use of biologic therapy by psoriasis
and PsA patients and use of conventional oral therapy by
PsA patients (Tables 4, 5). Fewer than 10 % of psoriasis
patients reported use of conventional oral therapy or bio-
logic therapy, compared with approximately 25 % of PsA
patients reporting use of each treatment. While 50 % of
PsA patients reported use of systemic therapy, half reported
no treatment or reported use of topical medications only,
leaving their joint disease untreated.
According to the physicians surveyed, use of conven-
tional oral and biologic therapies was much higher than
that reported by patients. Dermatologists reported use of
conventional oral therapy in 12.7 % of their psoriasis
patients and 22.9 % of their PsA patients, while rheuma-
tologists reported use in 57.1 % of PsA patients. Derma-
tologists reported use of biologic therapy in 35.8 % of
psoriasis patients and 46.9 % of PsA patients, while
rheumatologists reported use of biologic therapy in 52.7 %
of PsA patients. Some of these discrepancies in reported
treatment rates probably arose because patients were not
required to be seeing an HCP or receiving treatment to
participate in the MAPP survey. However, even the pro-
portion of physician-reported treatment indicates a level of
undertreatment.
3.6 Treatment Challenges and Burdens
3.6.1 Conventional Oral Therapy
Of the 250 respondents who had ever used conventional
oral therapies, about half found them burdensome. The
reasons for the treatment burden most often cited by
Table 3 Previous and current medical care in patients with psoriasis and psoriatic arthritis (PsA)
Previous/current medical care Psoriasis, n = 735 (%) PsA, n = 270 (%)
Seen an HCP in the previous 12 months 57.4 85.6
Type of HCP seen most often for psoriasis and PsA
Dermatologist 56.9 22.2
Rheumatologist 1.5 38.1
General medicine or primary care physician 30.2 28.1
Other/unknown 5.1 10.0
Not seen an HCP in the previous 12 months 42.6 14.4
Ever seen a dermatologist (for psoriasis) or rheumatologist (for PsA) 80.0 68.0
Reasons for not seeing an HCP
Symptoms were not bad enough 34.1 32.4
No symptoms 19.9 20.6
Did not think an HCP could help 18.9 23.5
Current treatment working 10.6 2.9
Cost or lack of insurance 7.0 8.8
Unable to get appointment 1.0 2.9
HCP healthcare provider
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patients were adverse effects and the need for labora-
tory monitoring (Fig. 2a). Patients most commonly
discontinued conventional oral therapy because of safety
and tolerability issues, or lack or loss of effectiveness
(Fig. 3a). Similarly, the main reasons for dermatologists
and rheumatologists not initiating or maintaining con-
ventional oral therapy in psoriasis and PsA patients
were related to long-term safety and tolerability
concerns (Fig. 3b, c). In addition, one quarter of
rheumatologists also cited lack of effectiveness as the
main reason for not initiating conventional oral therapy
for their PsA patients. Of the physicians who did not
prescribe conventional oral therapy, because of patient
refusal or concerns, the most common patient concerns
were related to long-term safety, tolerability, and life-
style modifications.
Fig. 2 Most common patient-
reported reasons for
conventional oral
therapy (a) and biologic
therapy (b) being burdensome
Table 4 Current treatment utilization in patients with moderate to severe psoriasis
Therapy Reported by psoriasis patients, n = 1005 (%)a Reported by dermatologists, n = 101 (%)b
Topical therapy 40.0 79.1
Conventional oral therapy 5.8 12.7
Biologic therapy 7.9 35.8
a Patients were asked to self-rate the severity of their disease on a 1–10 scale (1–3 for mild, 4–7 for moderate, 8–10 for severe)
b Treatment utilization is reported for patients with moderate to severe psoriasis, as estimated by dermatologists
Table 5 Current treatment utilization in patients with psoriatic arthritis (PsA)
Therapy Reported by PsA patients,
n = 270 (%)
Reported by dermatologists,
n = 101 (%)a
Reported by rheumatologists,
n = 100 (%)a




Biologic therapy 25.9 46.9 52.7
a Treatment utilization is reported for patients with moderate to severe PsA, as estimated by dermatologists or rheumatologists
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3.6.2 Biologic Therapy
Among 90 patients who were using injectable biologics
at the time of the survey, anxiety and fear related to
injections and side effects were the most common rea-
sons that 27 % cited for finding them burdensome
(Fig. 2b). As with conventional oral therapy, patients
most commonly discontinued biologic therapy because
of safety and tolerability concerns, and lack or loss of
effectiveness; however, 13.7 % of patients also reported
cost as a reason for discontinuing biologic therapy
(Fig. 4a).
Broad use of biologic agents was reported by three
quarters of rheumatologists versus one third of derma-
tologists, yet 82.2 % of dermatologists (versus 99.0 %
of rheumatologists) said they would initiate and manage
biologic therapy themselves if their patient were a
candidate. The main reasons that dermatologists and
rheumatologists cited for not initiating or continuing
biologic therapy were related to long-term safety and
tolerability issues, as well as cost (Fig. 4b, c).
3.7 Satisfaction with Current Treatment Options
The majority of psoriasis and PsA patients were somewhat
satisfied or very satisfied with the effectiveness of con-
ventional oral therapy (56.9 and 69.5 %, respectively) or
biologic therapy (77.7 and 83.5 %, respectively), with
more PsA patients than psoriasis patients reporting satis-
faction. However, 33.9 % of psoriasis patients and 39.7 %
of PsA patients reported being dissatisfied with the long-
term safety of conventional oral therapy. Dissatisfaction
with the long-term safety of biologic therapy was reported
by 31.8 % of psoriasis patients and 25.2 % of PsA patients.
Overall, 31.3 % of psoriasis patients and 40.7 % of PsA
patients reported that their primary goals of therapy,
including keeping symptoms at bay, reducing itching, and
decreasing flaking, were not met with their current
treatment.
In general, more physicians than patients reported sat-
isfaction with treatment effectiveness. Among dermatolo-
gists, 76.3 % reported satisfaction with conventional oral
therapy effectiveness and 99.0 % reported satisfaction with
Fig. 4 Most common reasons for patients discontinuing biologic
therapy (a) and for dermatologists (b) and rheumatologists (c) not
initiating or continuing biologic therapy
Fig. 3 Most common reasons for patients discontinuing conventional
oral therapy (a) and for dermatologists (b) and rheumatolo-
gists (c) not initiating or continuing conventional oral therapy
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biologic therapy effectiveness, while 69.0 and 97.0 % of
rheumatologists, respectively, reported satisfaction. How-
ever, 53.2 % of dermatologists and 17.0 % of rheumatol-
ogists were dissatisfied with the long-term safety of
conventional oral therapies; 17.8 % of dermatologists and
15.0 % of rheumatologists reported dissatisfaction with the
long-term safety of biologic agents. Nearly 80 % of der-
matologists and more than 50 % of rheumatologists
reported that they were somewhat or very concerned about
the overall long-term use of conventional oral or biologic
therapy.
Overall, most survey respondents (87.8 % of patients,
98.0 % of dermatologists, and 98.0 % of rheumatologists)
felt there was a strong or moderate need for better thera-
pies. Among patients, 51.5 % indicated that current ther-
apies can be worse than the condition itself, compared with
30.7 % of dermatologists and 12.0 % of rheumatologists.
In addition, 48.5 % of dermatologists and 31.0 % of
rheumatologists reported that an important issue is patients
leaving their practice because of frustration or dissatisfac-
tion with currently available therapies.
4 Discussion
MAPP was unique in its design as a large-scale, multina-
tional, population-based survey that included patients with
psoriasis and/or PsA, as well as physicians. The results of
the current report reflect the findings from the US
respondents, including patients, dermatologists, and
rheumatologists, with a goal of identifying the similarities
and discrepancies in patient and physician responses, as
well as the challenges and unmet needs of diagnosis,
assessment, and treatment.
To participate in the MAPP survey, patients were not
required to be under the care of a physician, receiving
treatment, or a member of a patient organization. A sub-
stantial proportion of patients who participated had not
seen an HCP for their psoriasis within the previous
12 months. The reported reasons included that they did not
feel an HCP could help, demonstrating frustration with the
current management options. This was mirrored by
approximately half of the dermatologists and one third of
the rheumatologists, who agreed that they were concerned
about patients leaving their practice because of frustration
or dissatisfaction with currently available therapies. Of
those patients who had seen an HCP within the previous
12 months, approximately 30 % of both psoriasis and PsA
patients saw a primary care physician, not a specialist,
which is slightly higher than the rate of 22 % recently
reported by the National Psoriasis Foundation (NPF) [17].
When asked about factors that affect disease severity,
patient and physician responses differed. Patients,
especially those with psoriasis, consistently placed more
emphasis on pruritus than did physicians. US psoriasis
patients [15] and global psoriasis patients [14] reported
itching as the most important factor contributing to disease
severity, followed by the location and size of lesions. In
contrast, just over 10 % of US dermatologists cited itching
as the most important factor. This finding may be related to
the fact that itching is not currently captured in most
physician assessments or in the most commonly used
psoriasis assessment tools, including those used in clinical
trials but not often in practice, such as the Psoriasis Area
and Severity Index and the physician’s global assessment
of disease severity [18]. Even among PsA patients, itching
was cited by nearly 15 % of patients as the most important
factor contributing to disease severity. Overall, these
findings suggest that patients may assess disease severity
differently from physicians, and tend to consider symptoms
beyond those usually assessed in a physician visit.
Improved communication between patients and physicians
may help to foster the understanding of all aspects of dis-
ease that impact patient quality of life.
Joint pain was reported by more than half of the patients
with a diagnosis of psoriasis alone. However, fewer than
20 % of dermatologists reported that their psoriasis
patients had joint pain. Although more than three quarters
of both dermatologists and rheumatologists agreed that PsA
may go undiagnosed because of failure to connect skin and
joint symptoms, fewer than 60 % of dermatologists dis-
cussed this risk with all of their psoriasis patients. A sep-
arate report recently highlighted the underdiagnosis of PsA
in dermatology treatment centers, where approximately
40 % of patients diagnosed with PsA by a rheumatologist
had not been diagnosed by their dermatologist [9].
The MAPP survey included additional questions about
managing PsA patients that may provide more insights into
the potential underdiagnosis of this disease. More than one
third of the surveyed US dermatologists reported that the
greatest challenge in managing their PsA patients was
differentiating PsA from other arthritic diseases. However,
fewer than 10 % felt they would need to refer to or involve
other specialists in the care of their PsA patients. The
surveyed US rheumatologists reported delayed referrals as
the second most common challenge in treating PsA
patients. Fewer than 40 % of physicians reported co-man-
agement of PsA patients. Most often, this relationship
consisted of a rheumatologist primarily being responsible
for prescribing decisions and a dermatologist monitoring
skin symptoms. A recent review and meta-analysis pro-
vided recommendations for dermatologists regarding
screening, diagnosing, and treating PsA patients [19].
Educating dermatologists to routinely discuss and evaluate
joint disease with their psoriasis patients—and providing
guidance on when to refer them to a rheumatologist—may
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bring about more timely diagnosis and treatment of patients
with PsA. Co-management and/or collaborative efforts
among dermatologists and rheumatologists may ensure that
psoriasis patients, while receiving care for their skin dis-
ease, are also adequately screened and further assessed for
the presence of PsA.
Despite expanding therapeutic options for managing
psoriasis and PsA patients, undertreatment remains a
challenge [9, 13]. Although approximately 70 % rated their
disease as moderate or severe [15], US patients partici-
pating in the MAPP survey reported low treatment rates,
with only about 10 % of psoriasis patients reporting
treatment with conventional oral or biologic therapy. US
dermatologists reported nearly three times greater current
use of conventional oral therapies and more than seven
times greater current use of biologic agents for their pso-
riasis patients than were reported by the surveyed US
patients. Likewise, while dermatologists and rheumatolo-
gists reported systemic therapy use in the majority of PsA
patients, only half of the PsA patients reported current use
of oral or biologic therapy. There are several possible
explanations for these discrepancies. Patients included in
the MAPP survey were not required to be seeing an HCP or
receiving treatment at the time of the survey, and patients
and physicians were not matched. Patients may have been
seeing another specialist or a primary care physician for
their disease. It is possible that seeing a primary care
physician rather than a physician specializing in dermato-
logic or rheumatic conditions contributed to the lower
treatment rates reported by the patients than by the par-
ticipating physicians. In addition, approximately 20 % of
psoriasis patients reported having no skin lesions as reasons
for not seeing an HCP, suggesting that treatment would not
be required. However, although higher rates of treatment
were reported by physicians than by patients, physicians
indicated that more than 30 % of patients were still not
receiving systemic therapy for their moderate to severe
psoriasis or for PsA at the time of the survey, in contrast to
guideline recommendations [20, 21]. In addition, other
surveys have also shown a high level of undertreatment. In
the 2011 NPF survey, up to one third of patients were not
receiving treatment for their moderate or severe psoriasis,
and of the patients who were receiving treatment, an esti-
mated 20–30 % were receiving topical monotherapy [13].
The complexity and time-consuming nature of treating
patients with psoriasis and PsA may contribute to
undertreatment. Most dermatologists reported that manag-
ing their psoriasis patients takes up more of their time than
managing other patients, and approximately one third of
dermatologists and rheumatologists described the care of
patients with PsA as complicated and time consuming.
Comorbidities, which were reported by the majority of
patients, may also be a contributing factor to the
complexity of treating psoriasis and PsA patients. In
addition, multiple physicians providing care to an indi-
vidual patient may lead to miscommunication or confusion
over roles in prescribing decisions, and may contribute to
lower treatment rates, emphasizing the importance of
communication among HCPs.
Dissatisfaction with current therapies may impact dis-
ease management and treatment. The most commonly cited
barriers to use of conventional oral therapy, across patients,
dermatologists, and rheumatologists, were concerns with
long-term safety and tolerability, and lack of effectiveness.
Patients also reported laboratory monitoring (16.4 %) and
lifestyle modification (7.0 %) as being among the top three
reasons contributing to the burden of these therapies.
Opinions on the barriers to use of biologic therapy differed
among patients and physicians. Patients reported anxiety
about and preparation of injections as the most common
reasons for therapy being burdensome, and concerns with
safety and tolerability or lack of effectiveness as reasons
for discontinuation, while dermatologists and rheumatolo-
gists cited lack of long-term safety and cost as the most
common reasons for not initiating or continuing biologic
therapy. The discrepancy in the importance of cost to
patients and physicians may reflect the effort required to
determine insurance eligibility and ensure reimbursement
before prescribing, which falls heavily on physicians ver-
sus patients, thus cost may not be considered an issue by
patients. The reasons for treatment discontinuation are
generally consistent with those found in a report of 1095
patients with moderate to severe psoriasis treated in der-
matology clinics within the USA [22]. A survey of NPF
members also found a high rate of dissatisfaction with
treatment among psoriasis patients (52.3 %) and PsA
patients (45.5 %), and cited adverse effects and efficacy as
the main reasons for patient discontinuation of biologic
therapy, along with inadequate insurance coverage and cost
[13].
Overall, the results of the MAPP survey among the US
respondents were consistent with those of global respon-
dents; however, some differences among physicians and
patients were noted. For patients with moderate to severe
psoriasis, a higher proportion of US dermatologists repor-
ted treating patients with biologic therapies, compared with
dermatologists globally (35.8 versus 19.6 %, respectively)
[16]. Likewise, higher proportions of US dermatologists
and rheumatologists reported treating PsA patients with
biologic therapies, compared with dermatologists and
rheumatologists globally (46.9–52.7 versus 30.6–33.4 %)
[16]. The challenges of managing psoriasis and PsA
patients identified by US physicians and global physicians
were similar; however, affordability of therapies was
considered a treatment challenge for psoriasis and PsA by a
greater proportion of US physicians than global physicians
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(28.7–57.4 % for US physicians versus 22.0–36.1 % for
global physicians) [16]. Survey responses among US
patients generally reflected those of the global population.
Differences between US patient responses and global
patient responses to the MAPP survey have been reviewed
previously; these include a higher proportion of US
patients than global patients reporting comorbidities such
as arthritis (48.3 versus 34.4 %) and hypertension (42.8
versus 32.7 %) [14, 15]. Treatment patterns reported by US
and global patients were generally similar, as were the
reasons identified for treatment discontinuation or for not
initiating treatments.
The findings from the MAPP survey are limited by
survey-related factors, which include lack of a control
group and reliance on accurate recall and interpretation of
questions. Because the survey was blinded, respondents
could not be contacted again to follow up or clarify
answers. Although patients and physician results are
compared within this report, the patients and physicians
were not matched, and the survey was not designed to
directly compare specific disease or treatment differences.
5 Conclusion
The findings from the US MAPP survey population high-
light the differences in perceptions between physicians and
patients with psoriasis and/or PsA regarding disease
severity and the impact on treatment choices. Patients with
psoriasis consistently reported that itching, which is usually
not captured in current assessment tools, is the most
influential factor in determining psoriasis severity, whereas
physicians reported the size or location of lesions as
leading factors contributing to disease severity. Psoriasis
patients should be screened and assessed routinely for
symptoms of PsA, and dermatologists need tools to dif-
ferentiate PsA from other rheumatic diseases. These
enhancements, along with improving referral rates and
collaboration between dermatologists and rheumatologists,
may lead to improved treatment of psoriasis and PsA.
Ongoing communication between patients and physicians
is needed for better understanding of perceptions of disease
severity, discussion and agreement on treatment options,
and establishment of realistic treatment goals. The need for
safe, effective, and easy-to-use therapies for both psoriasis
and PsA remains.
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